Wednesday, November 18th, 2026 from 12pm to 1:30pm – In French
You’ve probably already heard about KRAS inhibitors, one of the most promising advances in recent years in pancreatic cancer research. But how exactly do these treatments work? Where do clinical trials currently stand? And why do some patients develop resistance?
The FRAP network, in partnership with the French Pancreas Society (SFP) and the patient association Espoir Pancréas, invites you to a webinar to take stock of this topic, for patients and their loved ones.
It will take place on Wednesday, November 18, 2026, from 12:00 to 1:30 PM (Paris time).
Program
- Role and different classes of KRAS - Yvan Martineau, researcher
An introduction to the basics: what is the KRAS gene, why does it play a central role in pancreatic cancer, and what are the different families of treatments seeking to target it.
- Clinical trials, molecules, and accessibility - Pascal Hammel, physician-researcher
An overview of ongoing clinical trials, the different molecules in development, their accessibility for patients, and the role patient associations can play in helping patients access them.
- Mechanisms of resistance - Nicolas Jonckheere, researcher
Why do some tumors become resistant to KRAS inhibitors, and what research avenues currently help us better understand and anticipate this resistance?
Register
Link coming soon